BidaskClub Upgrades Dermira (NASDAQ:DERM) to “Hold”

BidaskClub upgraded shares of Dermira (NASDAQ:DERM) from a sell rating to a hold rating in a research report report published on Friday, BidAskClub reports.

A number of other research firms have also recently commented on DERM. Zacks Investment Research cut shares of Dermira from a buy rating to a hold rating in a research note on Wednesday, May 8th. Cantor Fitzgerald restated a buy rating and set a $25.00 target price on shares of Dermira in a research note on Friday, May 3rd. HC Wainwright restated a buy rating on shares of Dermira in a research note on Wednesday, May 8th. Finally, Mizuho upgraded shares of Dermira from a neutral rating to a buy rating and decreased their target price for the stock from $17.00 to $14.00 in a research note on Thursday, June 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $17.72.

NASDAQ DERM opened at $8.42 on Friday. Dermira has a 12 month low of $6.00 and a 12 month high of $15.48. The business’s 50 day moving average price is $8.67. The company has a current ratio of 8.42, a quick ratio of 8.08 and a debt-to-equity ratio of 4.95.

Dermira (NASDAQ:DERM) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.57. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%. The company had revenue of $66.65 million for the quarter, compared to analysts’ expectations of $34.16 million. As a group, analysts expect that Dermira will post -4.94 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in DERM. Vivo Capital LLC purchased a new stake in Dermira during the 1st quarter valued at approximately $9,485,000. Candriam Luxembourg S.C.A. purchased a new stake in Dermira during the 1st quarter valued at approximately $4,743,000. JPMorgan Chase & Co. grew its holdings in Dermira by 76.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 782,223 shares of the biopharmaceutical company’s stock valued at $7,025,000 after buying an additional 338,828 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in Dermira by 68.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 763,590 shares of the biopharmaceutical company’s stock valued at $10,347,000 after buying an additional 310,551 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in Dermira during the 1st quarter valued at approximately $2,635,000. 93.42% of the stock is owned by institutional investors and hedge funds.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Read More: What is a balanced fund?

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.